WO2001034565A3 - Protease inhibitors - Google Patents

Protease inhibitors Download PDF

Info

Publication number
WO2001034565A3
WO2001034565A3 PCT/US2000/030633 US0030633W WO0134565A3 WO 2001034565 A3 WO2001034565 A3 WO 2001034565A3 US 0030633 W US0030633 W US 0030633W WO 0134565 A3 WO0134565 A3 WO 0134565A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease inhibitors
solvate
hydrate
inhibition
inhibitor
Prior art date
Application number
PCT/US2000/030633
Other languages
French (fr)
Other versions
WO2001034565A2 (en
Inventor
Robert W Marquis Jr
Yu Ru
Daniel Frank Veber
Original Assignee
Smithkline Beecham Corp
Robert W Marquis Jr
Yu Ru
Daniel Frank Veber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Robert W Marquis Jr, Yu Ru, Daniel Frank Veber filed Critical Smithkline Beecham Corp
Priority to JP2001536514A priority Critical patent/JP2003513956A/en
Priority to EP00975608A priority patent/EP1235577A4/en
Publication of WO2001034565A2 publication Critical patent/WO2001034565A2/en
Publication of WO2001034565A3 publication Critical patent/WO2001034565A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

This invention relates to the compound of Formula (I): or a pharmaceutically acceptable salt, hydrate or solvate thereof, which is an inhibitor of cysteine proteases, particularly cathepsin K, and is useful in the treatment of diseases in which inhibition of bone loss or of cartilage degradation is a factor.
PCT/US2000/030633 1999-11-10 2000-11-08 Protease inhibitors WO2001034565A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2001536514A JP2003513956A (en) 1999-11-10 2000-11-08 Protease inhibitor
EP00975608A EP1235577A4 (en) 1999-11-10 2000-11-08 Protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16451199P 1999-11-10 1999-11-10
US60/164,511 1999-11-10

Publications (2)

Publication Number Publication Date
WO2001034565A2 WO2001034565A2 (en) 2001-05-17
WO2001034565A3 true WO2001034565A3 (en) 2001-10-04

Family

ID=22594826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030633 WO2001034565A2 (en) 1999-11-10 2000-11-08 Protease inhibitors

Country Status (3)

Country Link
EP (1) EP1235577A4 (en)
JP (1) JP2003513956A (en)
WO (1) WO2001034565A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
TR200101869T2 (en) * 1998-12-23 2002-01-21 Smithkline Beecham Corporation Protease Inhibitors.
JP2003513927A (en) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
US7071184B2 (en) 2000-03-21 2006-07-04 Smithkline Beecham Corporation Protease inhibitors
CO5280093A1 (en) * 2000-04-18 2003-05-30 Smithkline Beecham Corp TREATMENT METHODS
AU2001268407A1 (en) * 2000-06-14 2001-12-24 Smithkline Beecham Corporation Protease inhibitors
AU2001286983A1 (en) * 2000-09-01 2002-03-13 Smith Kline Beecham Corporation Method of treatment
JP2004196696A (en) * 2002-12-18 2004-07-15 Kyowa Hakko Kogyo Co Ltd Arthritis-preventing or treating agent
US20070293477A1 (en) * 2004-09-07 2007-12-20 Smithkline Beecham Corporation Novel Compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038687A1 (en) * 1998-12-23 2000-07-06 Smithkline Beecham Corporation Protease inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2285A1 (en) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Cysteine protease inhibitors.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038687A1 (en) * 1998-12-23 2000-07-06 Smithkline Beecham Corporation Protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1235577A4 *

Also Published As

Publication number Publication date
WO2001034565A2 (en) 2001-05-17
EP1235577A2 (en) 2002-09-04
EP1235577A4 (en) 2003-04-09
JP2003513956A (en) 2003-04-15

Similar Documents

Publication Publication Date Title
WO2002069901A3 (en) Cathepsin cysteine protease inhibitors
PL367821A1 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
WO2003075836A3 (en) Cathepsin cysteine protease inhibitors
CA2458684A1 (en) Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
AU2003243095A1 (en) New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
YU17402A (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
GEP20074098B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2001034565A3 (en) Protease inhibitors
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
WO2001034566A3 (en) Protease inhibitors
AR021241A1 (en) PROTEASE INHIBITORS
AU2002348473A1 (en) Nitrogen heterocycle inhibitors of aspartyl protease
IL154077A0 (en) New amidino derivatives and their use as thrombin inhibitors
MY132033A (en) New mandelic acid derivatives and their use as thrombin inhibitors
IL160068A0 (en) Mew mandelic acid derivatives and their use as thrombin inhibitors
WO2001079162A3 (en) INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
WO2002023784A3 (en) Cysteine protease inhibitors
ECSP993018A (en) NEW PROTEASE INHIBITORS, PARTICULARLY CYSTEINE AND SERINE PROTEASE INHIBITORS
AU2002348212A8 (en) Protease inhibitors of the coagulation cascade isolated from dysidea sponges
UY25369A1 (en) PROCEDURE FOR PREPARING PROTEASE INHIBITORS
MY139221A (en) Cathepsin cysteine protease inhibitors
ECSP993211A (en) PROTEASE INHIBITORS VI

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 10129680

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536514

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000975608

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000975608

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000975608

Country of ref document: EP